Potential of combination therapy of endolysin MR-10 and minocycline in treating MRSA induced systemic and localized burn wound infections in mice

International Journal of Medical Microbiology

Volumn 306, Issue 8, 2016, Pages 707-716

  Chopra, Shivani ^a   Harjai, Kusum ^a   Chhibber, Sanjay ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Burn wounds; Lysin; Minocycline; MRSA

Indexed keywords

ANTIBIOTIC AGENT; COLLAGEN; ENDOLYSIN MR 10; MINOCYCLINE; MYELOPEROXIDASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ENDOLYSIN; PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL LOAD; BACTERIOPHAGE; BLOOD; BURN INFECTION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIZATION; FEMALE; HISTOPATHOLOGY; LIVER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SKIN; SPLEEN; WOUND CONTRACTION; ANIMAL; ANIMAL STRUCTURES; BAGG ALBINO MOUSE; BURN; COMPLICATION; CYTOCHEMISTRY; DISEASE MODEL; DRUG EFFECTS; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PROCEDURES; SEPSIS; STAPHYLOCOCCAL INFECTIONS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME; WOUND INFECTION;

ADMINISTRATION, ORAL; ANIMAL STRUCTURES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BURNS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOPEPTIDASES; FEMALE; HISTOCYTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE, INBRED BALB C; MINOCYCLINE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; WOUND INFECTION;

EID: 85006022129     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2016.08.003     Document Type: Article

References (41)

1. Alexander, J.W., Mechanism of immunologic suppression in burn injury. J. Trauma 30 (1990), 70–75.
2. Altoparlak, U., Erol, S., Akcay, M.N., Celebi, F., Kadanali, A., The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 30 (2004), 660–664.
3. American Burn Association US, Burn incidence and treatment in the U.S. National health interview survey (1991–1993 data). 2000 www.ameriburn.org/history/USstatistics (accessed 05.07.13.).
4. Becker, S.C., Dong, S., Baker, J.R., Foster-Frey, J., Pritchard, D.G., Donovan, D.M., LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol. Lett. 294 (2009), 52–60.
5. Brans, T.A., Dutrieux, R.P., Hoekstra, M.J., Kreis, R.W., Du Pont, J.S., Histopathological evaluation of scalds and contact burns in the pig model. Burns 20 (1994), 548–551.
6. Chhibber, S., Kaur, T., Kaur, S., Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS One, 8, 2013, e56022.
7. Chhibber, S., Kaur, T., Kaur, S., Essential role of calcium in the infection process of broad-spectrum methicillin-resistant Staphylococcus aureus bacteriophage. J. Basic Microbiol. 54 (2014), 775–780.
8. Chopra, S., Harjai, K., Chhibber, S., Potential of sequential treatment with minocycline and S. aureus specific phage lysin in eradication of MRSA biofilms: an in vitro study. Appl. Microbiol. Biotechnol. 99 (2015), 3201–3210.
9. Chopra, S., Harjai, K., Chhibber, S., Antibiotic susceptibility of ica-positive and ica-negative MRSA in different phases of biofilm growth. J. Antibiot. 68 (2015), 15–22.
10. Church, D., Elsayed, S., Reid, O., Winston, B., Lindsay, R., Burn wound infections. Clin. Microbiol. Rev. 19 (2006), 403–434.
11. Dale, R.M.K., Schnell, G., Wong, J.P., Therapeutic efficacy of “Nubiotics” against burn wound infection by Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48 (2004), 2918–2923.
12. Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K.J., Fischetti, V.A., Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54 (2010), 1603–1612.
13. Erol, S., Altoparlak, U., Akcay, M.N., Celebi, F., Parlak, M., Changes of microbial flora and wound colonization in burned patients. Burns 30 (2004), 357–361.
14. Fischetti, V.A., Nelson, D., Schuch, R., Reinventing phage therapy: are the parts greater than the sum?. Nat. Biotechnol. 24 (2006), 1508–1511.
15. Fischetti, V.A., Bacteriophage lytic enzymes: novel anti infectives. Trends Microbiol. 13 (2005), 491–496.
16. Fischetti, V.A., Bacteriophage endolysins: a novel anti-infective to control gram-positive pathogens. Int. J. Med. Microbiol. 300 (2010), 357–362.
17. Goulden, V., Glass, D., Cunliffe, W.J., Safety of long-term high-dose Minocycline in the treatment of acne. Brit. J. Dermatol. 134 (1996), 693–695.
18. Greenberger, M.J., Strieter, R.M., Kunkel, S.L., Danforth, J.M., Laichalk, L.L., McGillicuddy, D.C., Standiford, T.J., Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumoniae. J. Infect. Dis. 173 (1996), 159–165.
19. Joshi, H., Chhikara, V., Arya, K., Pathak, R., Some undesirable effects reported in past five years related to Minocycline therapy: a review. Ann. Biol. Res. 1 (2010), 64–71.
20. Kandati, J., Pathapati, R.M., Ponugoti, M.L., Buchineni, M., Rao, P.S., Sateesh, S., Time related emergence of bacteria and their antibiogram of infected burns of patients during the hospital stay. Int. J. Curr. Microbiol. App. Sci. 4 (2015), 348–358.
21. López, R., García, E., García, P., Enzymes for anti-infective therapy: phage lysins. Drug Discov. Today 1 (2004), 469–474.
22. Lipsky, B.A., A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab. Res. Rev. 20 (2004), 68–77.
23. Loeffler, J.M., Nelson, D., Fischetti, V.A., Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294 (2001), 2170–2172.
24. Loessner, M.J., Bacteriophage endolysins-current state of research and applications. Curr. Opin. Microbiol. 8 (2005), 480–487.
25. Majumdar, M., Nayeem, N., Kamath, J.V., Asad, M., Evaluation of Tectona grandis leaves for wound healing activity. Pak. J. Pharm. Sci. 20 (2007), 120–124.
26. Malik, R., Chhibber, S., Protection with bacteriophage KØ1 against fatal Klebsiella penumoniae-induced burn wound infection in mice. J. Microbiol. Immunol. Infect. 42 (2009), 134–140.
27. National Center for Injury Prevention and Control US, United States fire/burn deaths and rates per 100,000. 2002 http://www.ameriburn.org/history/statistics (accessed 04.07.13).
28. Park, S., Rich, J., Hanses, F., Lee, J.C., Defects in innate immunity predispose C57BL/6J-Leprdb/Leprdb mice to infection by Staphylococcus aureus. Infect. Immun. 77 (2009), 1008–1014.
29. Pastagia, M., Euler, C., Chahales, P., Fuentes-Duculan, J., Krueger, J.G., Fischetti, V.A., A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and sensitive Staphylococcus aureus strains. Antimicrob. Agents Chemother. 55 (2011), 738–744.
30. Raghunath, D., Emerging antibiotic resistance in bacteria with special reference to India. J. Biosci. 33 (2008), 593–603.
31. Rennie, R.P., Jones, R.N., Mutnick, A.H., Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45 (2003), 287–293.
32. Ruhe, J.J., Menon, A., Tetracycline as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51 (2007), 3298–3303.
33. Rybak, M.J., Albrecht, L.M., Boike, S.C., Chandrasekar, P.H., Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicrob. Chemother. 25 (1990), 679–687.
34. Schuch, R., Nelson, D., Fischetti, V.A., A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418 (2002), 884–889.
35. Schuch, R., Lee, H.M., Schneider, B.C., Sauve, K.L., Law, C., Khan, B.K., Rotolo, J.A., Horiuchi, Y., Couto, D.E., Raz, A., Fischetti, V.A., Huang, D.B., Nowinski, R.C., Wittekind, M., Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J. Infect. Dis. 209 (2014), 1469–1478.
36. Serhan, C.N., Savill, J., Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6 (2005), 1191–1197.
37. Simonetti, O., Cirioni, O., Lucarini, G., Orlando, F., Ghiselli, R., Silvestri, C., Brescini, L., Rocchi, M., Provinciali, M., Guerrieri, M., Primio, R., Giacometti, A., Offidani, A., Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproetinase-9 modulation. Antimicrob. Chemother. 67 (2012), 191–201.
38. Stein, G.E., Craig, W.A., Tigecycline. A critical analysis. Clin. Infect. Dis. 43 (2006), 518–524.
39. Wayne, P.A., Clinical and Laboratory Standards Institute Manual. 2nd ed., 2006, Longman, New York.
40. Weigelt, J.H., Kaafarani, M., Itani, K.M., Swanson, R.N., Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188 (2004), 760–766.
41. Yother, J., Leopold, K., White, J., Fischer, W., Generation and properties of a Streptococcus pneumoniae mutant which does not require choline or analogs for growth. J. Bacteriol. 180 (1998), 2093–2101.